Market Overview

AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Share:

WALTHAM, Mass., March 04, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2019. Total revenues for the full year of 2019 totaled $327.8 million, including revenue of $167.9 million from Feraheme® (ferumoxytol injection), revenue of $122.1 million from Makena® (hydroxyprogesterone caproate injection), and revenue of $21.4 million from Intrarosa® (prasterone). The company reported an operating loss of $445.5 million and an adjusted EBITDA loss of $65.0 million in 2019.1

"Our financial results reported today reflect the successes and challenges of 2019. While we achieved record revenue for Feraheme and gained our third FDA approval in two years, we faced some challenges, namely the readout of the PROLONG study and the October Advisory Committee for Makena," said William Heiden, AMAG's president and chief executive officer. "We acknowledged the Makena challenges in our recently-completed strategic review, resulting in our decision to divest Intrarosa and Vyleesi®. We believe this decision will position the company well to focus on the continuing development of ciraparantag and AMAG-423, drive continued growth of Feraheme, and continue our work to retain patient access to Makena. Preparing for the future, the board of directors has initiated a search for my successor to lead the company on the next leg of the AMAG journey, serving shareholders and patients with unmet medical needs."

FINANCIAL RESULTS FOR THE PERIODS ENDED DECEMBER 31
Fourth Quarter Financial Results

($M) Three Months Ended December 31,
  2019   2018
Revenues $ 89.7     $ 88.1  
Feraheme 41.7     35.2  
Makena 25.6     46.9  
Intrarosa 6.5     5.9  
Other product revenue (0.4 )   0.1  
Collaboration revenue 16.3      
Costs and expenses $ 283.6     $ 106.9  
Cost of product sales 43.3     28.7  
Research and development 16.5     12.2  
Selling, general and administrative expenses 68.8     66.0  
Impairment of assets 155.0      
Operating loss $ (193.9 )   $ (18.8 )
Adjusted EBITDA1 $ (5.8 )   $ 1.5  

____________________________
1 See summaries of GAAP to non-GAAP adjustments at conclusion of this press release.

Revenues
During the fourth quarter ended December 31, 2019 revenue totaled $89.7 million, compared with $88.1 million for the same period in 2018.

  • In the fourth quarter of 2019 sales of Feraheme totaled $41.7 million, compared with $35.2 million in the same period in 2018, sales of Makena totaled $25.6 million, compared with $46.9 million in the same period in 2018, and sales of Intrarosa totaled $6.5 million, compared with $5.9 million in the same period in 2018.
  • Included in revenue for the fourth quarter of 2019 was $16.3 million of collaboration revenue recognized in connection with a termination and settlement agreement entered into with Daiichi Sankyo, Inc. (DSI) related to a clinical trial collaboration agreement that AMAG acquired as part of the Perosphere acquisition. Under the terms of the settlement agreement with DSI, AMAG received $10.0 million in cash and recognized an additional $6.3 million of deferred revenue in December 2019.

Costs and Expenses
Costs and expenses in the fourth quarter ended December 31, 2019 totaled $283.6 million, compared with $107.0 million in the same period in 2018.

  • During the fourth quarter of 2019, the company identified indicators of impairment for the Makena subcutaneous auto-injector, Intrarosa and Vyleesi asset groups related to i) the unfavorable FDA Advisory Committee recommendation for Makena on October 29, 2019 and ii) the completion of a strategic review, which resulted in the company's intention to divest Intrarosa and Vyleesi. Total impairment charges of $155.0 million were recorded in a separate operating expense line in the fourth quarter of 2019.

Operating Loss and Adjusted EBITDA

  • The company reported an operating loss in the fourth quarter ended December 31, 2019 of $193.9 million, which included the $155.0 million of impairment charges discussed above, compared to an operating loss of $18.8 million for the same period last year.
  • The company reported an adjusted EBITDA loss of $5.8 million in the fourth quarter of 2019, compared with adjusted EBITDA of $1.5 million for the same period last year.1

Full Year Financial Results
($M) Twelve Months Ended December 31,
  2019   2018
Revenues $ 327.8     $ 474.0  
Feraheme 167.9     135.0  
Makena 122.1     322.3  
Intrarosa 21.4     16.2  
Other product revenue (0.2 )   0.4  
Collaboration and other revenue 16.6     0.1  
Costs and expenses $ 773.3     $ 521.0  
Cost of product sales 107.2     215.9  
Research and development 64.9     44.8  
Acquired in-process research and development 74.9     32.5  
Selling, general and administrative expenses 286.6     227.8  
Impairment of assets 232.3      
Restructuring 7.4      
Operating loss $ (445.5 )   $ (47.0 )
Adjusted EBITDA1 $ (65.0 )   $ 120.8  

Revenues
Revenues totaled $327.8 million in 2019, compared with $474.0 million in 2018.

  • Feraheme achieved record revenue of $167.9 million in 2019, an increase of 24% over 2018, and market share of 17.7%. The overall IV iron market grew 12.0% in 2019 from 2018.
  • Makena revenues totaled $122.1 million in 2019, compared with $322.3 million in 2018. This decrease was primarily due to a decrease in sales of the Makena intramuscular (IM) product caused by IM supply disruptions and generic competition, which resulted in the company ultimately removing the IM product, including its authorized generic, from the market. Partially offsetting the decrease in Makena IM revenues was an increase in Makena subcutaneous auto-injector revenues.
  • Intrarosa revenues increased 32% to $21.4 million in 2019, compared with $16.2 million in 2018.

Costs and Expenses
Costs and expenses in 2019 totaled $773.3 million, compared with $521.0 million in 2018. This increase includes i) impairment charges of $232.3 million related to second quarter impairment charges of $77.4 million and the fourth quarter impairment charges described earlier, ii) a $74.9 million acquired in-process research and development charge related to the acquisition of Perosphere Pharmaceuticals, which closed in the first quarter of 2019, and iii) a restructuring charge of $7.4 million related to combining the Maternal Health and Women's Health sales forces in the first quarter of 2019.

  • Cost of product sales decreased $108.7 million year-over-year, primarily due to a decrease in amortization related to the Makena IM product that was fully impaired in the second quarter of 2019.
  • SG&A expenses increased $58.8 million to $286.6 million in 2019, compared with $227.8 million in 2018. SG&A expenses in 2018 included a reversal of $49.6 million related to a Makena sales milestone that the company determined was not likely to be paid. Excluding this expense reversal, SG&A increased by $9.2 million, which was primarily driven by the commercial launch of Vyleesi in September 2019.
  • Research and development expenses increased $20.0 million to $64.9 million in 2019, primarily related to the development costs for the ciraparantag and AMAG-423 programs.

Operating Loss and Adjusted EBITDA

  • The company reported an operating loss of $445.5 million in 2019, compared with an operating loss of $47.0 million in 2018.
  • The company reported an adjusted EBITDA loss of $65.0 million in 2019, compared with adjusted EBITDA of $120.8 million in 2018.1

Balance Sheet

  • As of December 31, 2019, the company's cash and investments totaled $171.8 million.
  • As of December 31, 2019 long-term debt totaled $320.0 million (representing the principal amount outstanding of the 2022 convertible notes).

"Despite the challenges that the company faced throughout 2019, the growth in Feraheme revenues emerged as a bright spot for the year. Even with a soft fourth quarter for Makena, we managed our spend to achieve our adjusted EBITDA financial guidance for the year," said Ted Myles, AMAG's chief operating officer and chief financial officer. "For 2020, we have guided to a return to profitability based on revenues of $255 million at the midpoint. We believe that our capital allocation strategy, which includes the divestiture of Intrarosa and Vyleesi and associated expense reductions, positions us well to focus on our core value drivers. AMAG's unique portfolio combines the opportunity to generate positive cash flows from commercial products while advancing a potentially exciting pipeline of development products."

2020 FINANCIAL GUIDANCE2
The company reaffirms the following financial guidance for 2020.

($M) 2020 Financial Guidance
Total revenue $230 - $280
Operating income $2 - $32
Non-GAAP adjusted EBITDA $20 - $50

2 See reconciliation of 2020 GAAP to non-GAAP financial guidance at conclusion of this press release.

2020 KEY PRIORITIES

  • Complete successful CEO transition 
  • Divest Intrarosa and Vyleesi to align with the new strategic direction 
  • Drive continued Feraheme growth 
  • Work with the FDA to maintain patient access to Makena  
  • Advance ciraparantag and AMAG-423 development programs  
  • Pursue ex-U.S. portfolio partnering opportunities 
  • Meet or exceed financial guidance 

CONFERENCE CALL AND WEBCAST ACCESS
AMAG Pharmaceuticals, Inc. will host a conference call and webcast today at 8:00 a.m. EST to discuss the company's fourth quarter and full year 2019 financial results.

DIAL-IN NUMBER
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 5865557

Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 5865557

A telephone replay will be available from approximately 11:00 a.m. ET on March 4, 2020 through midnight on March 11, 2020.

The webcast with slides will be accessible through the Investors section of AMAG's website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.

USE OF NON-GAAP FINANCIAL MEASURES
AMAG has presented certain non-GAAP financial measures, including non-GAAP adjusted EBITDA (earnings before income taxes, depreciation and amortization). These non-GAAP financial measures exclude certain amounts, expenses or income, from the corresponding financial measures determined in accordance with accounting principles generally accepted in the U.S. (GAAP). Management believes this non-GAAP information is useful for investors, taken in conjunction with AMAG's GAAP financial statements, because it provides greater transparency regarding AMAG's operating performance. Management uses these measures, among other factors, to assess and analyze operational results and trends and to make financial and operational decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of AMAG's operating results as reported under GAAP, not as a substitute for GAAP. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. The determination of the amounts that are excluded from non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts. Reconciliations between these non-GAAP financial measures and the most comparable GAAP financial measures are included in the tables accompanying this press release.

ABOUT AMAG
AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging our development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas, including women's health. For additional company information, please visit www.amagpharma.com.

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking information about AMAG Pharmaceuticals, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, beliefs about the performance of AMAG's commercially available products; beliefs regarding AMAG's ability to drive continued Feraheme growth; expectations for ciraparantag and AMAG-423 studies, including development timelines; AMAG's expectations regarding its ability to successfully divest Intrarosa and Vyleesi and the effect and amount of associated expense reductions; AMAG's expectations regarding its ability to ensure continued patient access to Makena and the associated effect on cash flow; beliefs regarding AMAG's ability to return to profitability; expectations that AMAG remains on track to return to positive adjusted EBITDA in 2020 and other 2020 financial guidance; plans to search for a successor to AMAG's president and chief executive officer, and the ability to affect a smooth transition William Heiden and the ability to effect a successful transition; plans to pursue ex-U.S. portfolio partnering opportunities; 2020 financial guidance, including forecasted GAAP revenue and operating loss and non-GAAP adjusted EBITDA; and beliefs regarding AMAG's ability to optimize the value of its portfolio to maximize shareholder value are based on management's current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Such risks and uncertainties include, among others, risks that the FDA will withdraw approval of Makena in line with the recommendation of the Advisory Committee; the FDA could take other adverse action related to Makena given the findings and recommendation of the Advisory Committee; AMAG may not be able to generate additional efficacy data that will be satisfactory to the FDA (if the FDA permits AMAG to submit additional data to support or as a condition to the continued commercialization of Makena); healthcare providers may be reluctant to continue to prescribe the Makena auto-injector or the FDA may require that the Makena label include information on the PROLONG study, restrictions to the current indication or the insertion of new warnings or precautions; AMAG is unable to generate sufficient cash to satisfy its debt obligations and could face challenges undertaking fundraising, restructuring or strategic transactions in order to meet these obligations, including under convertible notes due June 1, 2022; AMAG will be significantly dependent on sales of Feraheme to support its ongoing operations, including its development pipeline, and Feraheme could face increased competition in the near term, including as a result of the recent approval of Monoferric® or if Sandoz's ANDA is approved; that AMAG  will face difficulties or delays in appointing a chief executive officer to succeed Mr. Heiden or otherwise be unable to successfully transition to a new CEO; AMAG will not be able to divest Intrarosa or Vyleesi in the expected timeframe, or at all, or that any transaction will be on terms that are favorable to AMAG or that yield any value for its shareholders; that the anticipated benefits of such a divestiture, including anticipated expense reductions, will not be realized at expected levels, or at all; that AMAG may be unable to gain approval of its product candidates, including AMAG-423 and ciraparantag, on a timely basis, or at all; that such approvals, if obtained, will include unanticipated restrictions or warnings and that the costs and time investments for AMAG's development efforts will be higher than anticipated, or that AMAG has over-estimated the market and potential revenues for its products and product candidates, if approved, including AMAG-423 and ciraparantag; that AMAG will be unable to successfully identify and enter into partnerships with out-licensees for its product candidates in ex-U.S. territories, which could delay the commercialization of those product candidates in certain geographies, as well as those risks identified in AMAG's filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2018, its Quarterly Report on Form 10-Q for the quarters ended March 31, 2019, June 30, 2019 and September 30, 2019, and subsequent filings with the SEC (including its upcoming Annual Report on Form 10-K for the year ended December 31, 2019), which are available at the SEC's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect AMAG's results of operations, its profitability and its cash flows, which would, in turn, have a significant and adverse impact on AMAG's stock price. AMAG cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. AMAG Pharmaceuticals®, the logo and designs, Feraheme® and Vyleesi ® are registered trademarks of AMAG Pharmaceuticals, Inc. Makena® is a registered trademark of AMAG Pharma USA, Inc. Intrarosa® is a registered trademark of Endoceutics, Inc. Other trademarks referred to in this report are the property of their respective owners.

- Tables Follow -


AMAG Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(unaudited, amounts in thousands, except for per share data)

  Three Months Ended December 31,   Year Ended December 31,
  2019   2018   2019   2018
Revenues:              
Feraheme $ 41,653     $ 35,204     $ 167,947     $ 135,001  
Makena 25,601     46,888     122,064     322,265  
Intrarosa 6,520     5,888     21,417     16,218  
Other (395 )   67     (238 )   368  
Total product sales, net 73,379     88,047     311,190     473,852  
Collaboration revenue 16,299         16,400      
Other revenue 31     75     161     150  
Total revenues 89,709     88,122     327,751     474,002  
Costs and expenses:              
Cost of product sales 43,322     28,716     107,193     215,892  
Research and development expenses 16,476     12,211     64,853     44,846  
Acquired in-process research and development         74,856     32,500  
Selling, general and administrative expenses 68,873     66,030     286,600     227,810  
Impairment of assets 154,978         232,336      
Restructuring expenses         7,420      
Total costs and expenses 283,649     106,957     773,258     521,048  
Operating loss (193,940 )   (18,835 )   (445,507 )   (47,046 )
Other income (expense):              
Interest expense (6,510 )   (6,571 )   (25,709 )   (51,971 )
Loss on debt extinguishment             (35,922 )
Interest and dividend income 636     2,120     4,285     5,328  
Other (expense) income (134 )   (10 )   428     (74 )
Total other expense, net (6,008 )   (4,461 )   (20,996 )   (82,639 )
Loss from continuing operations before income taxes (199,948 )   (23,296 )   (466,503 )   (129,685 )
Income tax (benefit) expense (21 )   (2,550 )   (47 )   39,654  
Net loss from continuing operations (199,927 )   (20,746 )   (466,456 )   (169,339 )
               
Discontinued operations:              
Income from discontinued operations             18,873  
Gain on sale of CBR business     (2,506 )       87,076  
Income tax expense     (975 )       2,371  
Net (loss) income from discontinued operations     (1,531 )       103,578  
               
Net loss $ (199,927 )   $ (22,277 )   $ (466,456 )   $ (65,761 )
               
Basic and diluted earnings per share:              
Loss from continuing operations $ (5.89 )   $ (0.60 )   $ (13.71 )   $ (4.92 )
Income from discontinued operations     (0.04 )       3.01  
Total $ (5.89 )   $ (0.64 )   $ (13.71 )   $ (1.91 )
               
Weighted average shares outstanding used to compute earnings per share (basic and diluted): 33,945     34,560     34,030     34,394  
               


AMAG Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(unaudited, amounts in thousands)

  December 31, 2019   December 31, 2018
ASSETS      
Current assets:      
Cash and cash equivalents $ 113,009     $ 253,256  
Marketable securities 58,742     140,915  
Accounts receivable, net 94,163     75,347  
Inventories 31,553     26,691  
Prepaid and other current assets 19,100     18,961  
Note receivable     10,000  
Total current assets 316,567     525,170  
Property and equipment, net 4,116     7,521  
Goodwill 422,513     422,513  
Intangible assets, net 23,620     217,033  
Operating lease right-of-use asset 23,286      
Deferred tax assets 630     1,260  
Restricted cash 495     495  
Other long-term assets     1,467  
Total assets $ 791,227     $ 1,175,459  
LIABILITIES AND STOCKHOLDERS' EQUITY      
Current liabilities:      
Accounts payable $ 27,021     $ 14,487  
Accrued expenses 177,079     129,537  
Current portion of convertible notes, net     21,276  
Current portion of operating lease liability 4,077      
Current portion of acquisition-related contingent consideration 17     144  
Total current liabilities 208,194     165,444  
Long-term liabilities:      
Convertible notes, net 277,034     261,933  
Long-term operating lease liability 19,791      
Long-term acquisition-related contingent consideration     215  
Other long-term liabilities 89     1,212  
Total liabilities 505,108     428,804  
       
Commitments and Contingencies (Note P)      
Stockholders' equity:      
Preferred stock, par value $0.01 per share, 2,000,000 shares authorized; none issued      
Common stock, par value $0.01 per share, 117,500,000 shares authorized; 33,999,081 and 34,606,760 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively 339     346  
Additional paid-in capital 1,297,917     1,292,736  
Accumulated other comprehensive loss (3,239 )   (3,985 )
Accumulated deficit (1,008,898 )   (542,442 )
Total stockholders' equity 286,119     746,655  
Total liabilities and stockholders' equity $ 791,227     $ 1,175,459  


AMAG Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited, amounts in thousands, except for per share data)

  Years Ended December 31,
  2019   2018
Cash flows from operating activities:      
Net loss $ (466,456 )   $ (65,761 )
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:      
Depreciation and amortization 27,324     172,223  
Impairment of long-lived assets 232,336      
Provision for bad debt expense     678  
Amortization of premium/discount on purchased securities (95 )   87  
Write-down of inventory 19,767     5,176  
(Gain) loss on disposal of fixed assets     (99 )
Non-cash equity-based compensation expense 19,198     19,916  
Non-cash IPR&D expense 18,029      
Loss on debt extinguishment     35,922  
Amortization of debt discount and debt issuance costs 15,242     15,658  
(Gain) loss on sale of marketable securities, net (265 )   (1 )
Change in fair value of contingent consideration (270 )   (49,607 )
Deferred income taxes 404     41,166  
Non-cash lease expense 2,725      
Gain on sale of the CBR business     (87,076 )
Transaction costs     (14,111 )
Changes in operating assets and liabilities:      
Accounts receivable, net (18,816 )   16,995  
Inventories (19,253 )   (454 )
Prepaid and other current assets (113 )   (6,097 )
Accounts payable and accrued expenses 52,747     (32,568 )
Deferred revenues (6,400 )   8,658  
Other assets and liabilities (1,800 )   95  
Net cash (used in) provided by operating activities (125,696 )   60,800  
Cash flows from investing activities:      
Proceeds from sales or maturities of marketable securities 98,321     85,342  
Purchases of marketable securities (14,815 )   (89,956 )
Milestone payment for Vyleesi developed technology (60,000 )    
Proceeds from the sale of the CBR business     519,303  
Note receivable     (10,000 )
Capital expenditures (2,544 )   (2,534 )
Net cash provided by investing activities 20,962     502,155  
Cash flows from financing activities:      
Long-term debt principal payments     (475,000 )
Payments to repurchase 2019 Convertible Notes (21,417 )    
Payment of premium on debt extinguishment     (28,054 )
Payment of contingent consideration (72 )   (119 )
Payments for repurchases of common stock (13,730 )    
Proceeds from the issuance of common stock under the ESPP 1,506      
Proceeds from the exercise of common stock options 30     3,881  
Payments of employee tax withholding related to equity-based compensation (1,830 )   (2,682 )
Net cash used in financing activities (35,513 )   (501,974 )
Net (decrease) increase in cash, cash equivalents and restricted cash (140,247 )   60,981  
Cash, cash equivalents and restricted cash at beginning of the year 253,751     192,770  
Cash, cash equivalents and restricted cash at end of the year $ 113,504     $ 253,751  
       
Supplemental data of cash flow information:      
Cash (refunded) paid for taxes $ (202 )   $ 5,345  
Cash paid for interest $ 10,667     $ 48,757  
Non-cash investing and financing activities:      
Right-of-use assets obtained in exchange for lease obligations $ 18,455     $  
Settlement of note receivable in connection with Perosphere acquisition $ 10,000     $  


AMAG Pharmaceuticals, Inc.
Reconciliation of Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations
Three Months Ended December 31, 2019
(unaudited, amounts in thousands)

  Revenue   Cost of product sales   Research & development   Selling, general & administrative   Asset impairment charges   Operating Loss / Adjusted EBITDA
GAAP $ 89,709     $ 43,322     $ 16,476     $ 68,873     $ 154,978     $ (193,940 )
Depreciation and intangible asset amortization     (12,666 )   (101 )   (684 )        
Stock-based compensation     (245 )   (793 )   (3,779 )        
Charges related to impairment     (14,893 )           (154,978 )    
Non-GAAP Adjusted $ 89,709     $ 15,518     $ 15,582     $ 64,410     $     $ (5,801 )


AMAG Pharmaceuticals, Inc.
Reconciliation of Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations
Three Months Ended December 31, 2018
(unaudited, amounts in thousands)

  Revenue   Cost of product sales   Research & development   Selling, general & administrative   Operating Loss / Adjusted EBITDA
GAAP $ 88,122     $ 28,716     $ 12,211     $ 66,030     $ (18,835 )
Depreciation and intangible asset amortization     (13,714 )   (9 )   (372 )    
Non-cash inventory step-up adjustments     (126 )            
Stock-based compensation     (215 )   (637 )   (4,465 )    
Adjustments to contingent consideration             432      
Acquisition related costs             (1,257 )    
Non-GAAP Adjusted $ 88,122     $ 14,661     $ 11,565     $ 60,368     $ 1,528  


AMAG Pharmaceuticals, Inc.
Reconciliation of Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations
Twelve Months Ended December 31, 2019
(unaudited, amounts in thousands)

  Revenue   Cost of product sales   Research & development   Selling, general & administrative   Asset impairment charges   Acquired IPR&D   Restructuring   Operating Loss / Adjusted EBITDA
GAAP $ 327,751     $ 107,193     $ 64,853     $ 286,600     $ 232,336     $ 74,856     $ 7,420     $ (445,507 )
Depreciation and intangible asset amortization     (24,764 )   (572 )   (1,988 )                
Stock-based compensation     (871 )   (2,844 )   (14,818 )                
Acquired IPR&D                     (74,856 )        
Charges related to impairment     (19,729 )           (232,336 )            
Restructuring charges                         (7,420 )    
Acquisition related costs             (270 )                
Non-GAAP Adjusted $ 327,751     $ 61,829     $ 61,437     $ 269,524     $     $     $     $ (65,039 )


AMAG Pharmaceuticals, Inc.
Reconciliation of Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations
Twelve Months Ended December 31, 2018
(unaudited, amounts in thousands)

  Revenue   Cost of product sales   Research & development   Selling, general & administrative   Acquired IPR&D   Operating Loss / Adjusted EBITDA
GAAP $ 474,002     $ 215,892     $ 44,846     $ 227,810     $ 32,500     $ (47,046 )
Depreciation and intangible asset amortization     (158,446 )   (21 )   (1,592 )        
Non-cash inventory step-up adjustments     (3,728 )                
Stock-based compensation     (802 )   (2,533 )   (16,614 )        
Adjustments to contingent consideration             49,607          
Acquired IPR&D                 (32,500 )    
Acquisition related costs             (1,257 )        
Non-GAAP Adjusted $ 474,002     $ 52,916     $ 42,292     $ 257,954     $     $ 120,840  


AMAG Pharmaceuticals, Inc.
Reconciliation of 2019 Financial Guidance of Non-GAAP Adjusted EBITDA
(Unaudited, amounts in millions)

Operating income $2 - $32
Depreciation 2
Stock-based compensation 16
Adjusted EBITDA $20 - $50


AMAG Pharmaceuticals, Inc.
Share Count Reconciliation
(unaudited, amounts in millions)

  Three Months Ended December 31,   Twelve Months Ended December 31,  
  2019   2018   2019   2018  
Weighted average basic shares outstanding 33.9     34.6     34.0     34.4    
Employee equity incentive awards   3   3   3   3
GAAP diluted shares outstanding 33.9     34.6     34.0     34.4    
Employee equity incentive awards   4 0.3   4   4 0.3   4
Non-GAAP diluted shares outstanding 33.9     34.9     34.0     34.7    

3 Employee equity incentive awards would be anti-dilutive in this period.
4 Reflects the non-GAAP dilutive impact of employee equity incentive awards.


CONTACTS:
Investors:
Linda Lennox
908-627-3424

Media:
Sarah Connors
781-296-0722 

Primary Logo

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com